<div id="readability-page-1"><p>KALA BIO, Inc. (NASDAQ:KALA - Free Report)'s stock is scheduled to reverse split before the market opens on Monday, May 11th. The 1-50 reverse split was announced on Thursday, May 7th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 8th.</p><h2>KALA BIO Price Performance</h2><ul><li>Kala Pharmaceuticals Up 400% In The Past Month, What's Next ?</li></ul><p>Shares of NASDAQ:KALA traded down $0.03 during mid-day trading on Thursday, reaching $0.08. 8,127,962 shares of the company traded hands, compared to its average volume of 6,040,966. The company's 50 day moving average price is $0.23 and its 200-day moving average price is $0.51. The firm has a market cap of $77.24 million, a PE ratio of -0.02 and a beta of -2.23. KALA BIO has a 52 week low of $0.08 and a 52 week high of $20.60. </p><p>KALA BIO (NASDAQ:KALA - Get Free Report) last released its earnings results on Wednesday, April 15th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $1.03. </p><h2>Analyst Ratings Changes</h2><p>Separately, Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of KALA BIO in a research note on Friday, March 27th. One investment analyst  has rated the stock with a Buy rating, four have issued  a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus target price of $20.38.</p><p><b>Get Our Latest Analysis on KALA BIO</b></p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of  KALA BIO during the fourth quarter valued at approximately $48,000.  XTX Topco Ltd bought a new stake in shares of  KALA BIO in the second quarter worth about $62,000.  Jane Street Group LLC purchased a new stake in shares of  KALA BIO in the fourth quarter worth about $80,000.  Geode Capital Management LLC increased its stake in  KALA BIO by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock worth $268,000 after acquiring an additional 1,534 shares during the last quarter.  Finally, Baker BROS. Advisors LP grew its holdings in shares of  KALA BIO by 83.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,804,055 shares of the company's stock valued at $1,003,000 after purchasing an additional 818,962 shares in the last quarter. 24.61% of the stock is currently owned by institutional investors. </p><h2>KALA BIO Company Profile</h2> (Get Free Report)<p>KALA Bio <span>NASDAQ: KALA<span></span></span> is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company's proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.  </p><p>Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than KALA BIO</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in KALA BIO Right Now?</h2><p>Before you consider KALA BIO, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KALA BIO wasn't on the list.</p><p>While KALA BIO currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KALA

ARKG

<p>KALA BIO, Inc. (NASDAQ:KALA) is set to undergo a 1-50 reverse stock split on May 11th, following an announcement on May 7th. Share adjustments will occur after market close on May 8th. The stock has seen significant volatility, trading down to $0.08 recently, with a market cap of $77.24 million. Analysts have mixed ratings, with one Buy, four Hold, and one Sell. KALA BIO focuses on developing therapies for ocular diseases, including its FDA-approved product, Eysuvis.</p>

KALA BIO Stock Scheduled to Reverse Split on Monday, May 11th (NASDAQ:KALA)